Epithalon vs NAD+: Two Approaches to Ageing Research
One is a tetrapeptide, the other is not a peptide at all. Shelving them together obscures how differently each is characterised.
Epithalon and NAD+ both appear under the heading of ageing research and are sometimes shelved together as “longevity compounds”. Chemically and mechanistically they have almost nothing in common — one is a peptide, the other is not a peptide at all — and the comparison is useful mainly for showing how differently the same research question can be approached.
What each one is
Epithalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, developed in Russian research institutes as a synthetic analogue of a pineal extract designated epithalamin. Four residues, molecular weight around 390 g/mol.
NAD+ — nicotinamide adenine dinucleotide — is a coenzyme, not a peptide. It is a dinucleotide built from nicotinamide, adenine, two riboses and two phosphates, molecular weight around 663 g/mol. It contains no amino acids and no peptide bonds.
That difference matters for everything downstream, including how each is analysed.
Different mechanisms entirely
Epithalon is studied primarily in relation to telomerase. The published work — largely from the originating institutes — reports effects on telomerase activity in cell culture and describes possible interaction with promoter regions of the telomerase gene. The proposed mechanism is transcriptional.
NAD+ is a metabolic cofactor with a well-established, textbook role: it is the primary electron carrier in redox reactions across central metabolism. Its relevance to ageing research comes from a second role — as a substrate consumed by sirtuins and by PARP enzymes, both of which are implicated in DNA repair and metabolic regulation. NAD+ levels decline with age in multiple tissues, which is the observation the field is built on.
So one is a signalling molecule proposed to influence gene expression, and the other is a substrate whose availability limits enzyme activity. These are not comparable mechanisms.
The state of the evidence
| Epithalon | NAD+ | |
|---|---|---|
| Basic biochemistry | Limited outside originating groups | Extensively established, decades old |
| Ageing-specific claims | Mostly from a small number of groups | Active, contested, large literature |
| Independent replication | Limited | Extensive for the biochemistry |
| Main open question | Whether the reported effects generalise | Whether raising levels produces the expected downstream effects |
The NAD+ literature is large and its central question is genuinely unsettled — the decline with age is well documented; whether intervening on it changes outcomes is not. The epithalon literature is smaller and more concentrated, and much of it is published in Russian-language journals with limited indexing. Neither of those facts is disqualifying, but they are different kinds of uncertainty and worth keeping separate.
Analytical differences
This is where the chemical distinction becomes practical.
Epithalon is a tetrapeptide and is verified like one: reverse-phase HPLC for purity, mass spectrometry against a theoretical mass calculated from the sequence. At four residues there is almost nowhere for an impurity to hide, so a certificate should be clean and unambiguous.
NAD+ is not verified the same way. It has no peptide bond, so 214 nm detection is not the relevant method; it absorbs at 260 nm like other nucleotides. It is also hygroscopic and degrades in solution faster than most peptides, particularly at alkaline pH, and its degradation products are distinct from anything in peptide chemistry.
A supplier applying a peptide certificate template to NAD+ — reporting purity at 214 nm and comparing to a “sequence” — has not understood what they are analysing.
Our epithalon article and NAD+ article cover each in detail.
Both compounds are supplied strictly for laboratory research. We do not provide dosing information and nothing here describes use in humans.
All products and information referenced are for in-vitro research and laboratory use only. Nothing here is medical advice, and no therapeutic claim is made or implied.